Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
---|---|---|---|---|---|
Dec 31, 2024 | = | ÷ | |||
Dec 31, 2023 | = | ÷ | |||
Dec 31, 2022 | = | ÷ | |||
Dec 31, 2021 | = | ÷ | |||
Dec 31, 2020 | = | ÷ | |||
Dec 31, 2019 | = | ÷ | |||
Dec 31, 2018 | = | ÷ | |||
Dec 31, 2017 | = | ÷ | |||
Dec 31, 2016 | = | ÷ | |||
Dec 31, 2015 | = | ÷ | |||
Dec 31, 2014 | = | ÷ | |||
Dec 31, 2013 | = | ÷ | |||
Dec 31, 2012 | = | ÷ | |||
Dec 31, 2011 | = | ÷ | |||
Dec 31, 2010 | = | ÷ | |||
Dec 31, 2009 | = | ÷ | |||
Dec 31, 2008 | = | ÷ | |||
Dec 31, 2007 | = | ÷ | |||
Dec 31, 2006 | = | ÷ | |||
Dec 31, 2005 | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The analyzed annual financial data reveals several noteworthy trends regarding liquidity and short-term financial stability.
- Current Assets
- From 2005 to 2024, current assets increased significantly overall, with some fluctuations. Starting at approximately $385 million in 2005, they rose to a peak exceeding $13.2 billion by 2022, followed by a slight decrease in the last two years under review, ending near $9.6 billion in 2024. This demonstrates an overall strong growth trend in short-term asset accumulation, indicative of expanding operational scale or improved cash and receivables management.
- Current Liabilities
- Current liabilities also increased over the period but at a slower and more variable pace compared to current assets. Beginning at about $100 million in 2005, current liabilities grew to approximately $3.56 billion by 2024. The liabilities showed relatively steady growth with some periods of more rapid increase (notably between 2009 and 2010, and from 2019 onwards), indicating rising obligations likely linked to increased business activities or financing needs.
- Current Ratio
- The current ratio, a key indicator of liquidity, started at a high level of 3.84 in 2005, indicating strong short-term financial health. This ratio experienced volatility across the years, dropping to lows around 2.23 in 2010 and 2.31 in 2016. However, from 2016 onward, the ratio generally improved, peaking at 4.83 in 2022 before declining to 2.69 in 2024. This variability suggests fluctuating liquidity conditions, with sufficient buffers to cover liabilities most years but some pressure emerging by the end of the period.
In summary, the entity maintained a solid liquidity position overall, supported by substantial growth in current assets outpacing increases in current liabilities through most of the period. The fluctuations in the current ratio highlight periods of shifting short-term financial dynamics. The recent decline in the current ratio, despite still sizeable current assets, may warrant further review to ensure continued ability to meet short-term obligations without strain.
Comparison to Competitors
Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | ||||||||||||
Dec 31, 2023 | ||||||||||||
Dec 31, 2022 | ||||||||||||
Dec 31, 2021 | ||||||||||||
Dec 31, 2020 | ||||||||||||
Dec 31, 2019 | ||||||||||||
Dec 31, 2018 | ||||||||||||
Dec 31, 2017 | ||||||||||||
Dec 31, 2016 | ||||||||||||
Dec 31, 2015 | ||||||||||||
Dec 31, 2014 | ||||||||||||
Dec 31, 2013 | ||||||||||||
Dec 31, 2012 | ||||||||||||
Dec 31, 2011 | ||||||||||||
Dec 31, 2010 | ||||||||||||
Dec 31, 2009 | ||||||||||||
Dec 31, 2008 | ||||||||||||
Dec 31, 2007 | ||||||||||||
Dec 31, 2006 | ||||||||||||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc. | Health Care | |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).